{Reference Type}: English Abstract
{Title}: [Efficacy and safety analysis of hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in low-risk myelodysplastic syndromes patients].
{Author}: Lyu Y;Lin ZH;Yang L;Liu H;
{Journal}: Zhonghua Xue Ye Xue Za Zhi
{Volume}: 45
{Issue}: 3
{Year}: 2024 Mar 14
暂无{DOI}: 10.3760/cma.j.cn121090-20230825-00089
{Abstract}: Myelodysplastic syndromes is a heterogeneous group of myeloid neoplastic disorders originating from hematopoietic stem cells and manifesting as pathological bone marrow hematopoiesis and a high risk of transformation to acute myeloid leukemia. In low-risk patients, the therapeutic goal is to improve hematopoiesis and quality of life. Roxadustat is the world's first oral small-molecule hypoxia-inducible factor prolyl hydroxylase inhibitor, which, unlike conventional erythropoietin, corrects anemia through various mechanisms. In this study, we retrospectively analyzed the changes in anemia, iron metabolism, lipids and inflammatory indexes in patients with low-risk myelodysplastic syndromes to evaluate its therapeutic efficacy and safety, and to provide theoretical and practical data for the application of roxadustat in myelodysplastic syndromes.<BR>骨髓增生异常综合征是起源于造血干细胞的一组异质性髓系肿瘤性疾病，表现为骨髓病态造血和高风险向急性髓系白血病转化。低危患者的治疗主要是改善造血，提高生活质量。罗沙司他是全球首个口服小分子低氧诱导因子脯氨酰羟化酶抑制剂，与传统红细胞生成素不同，罗沙司他通过多种途径纠正贫血。本研究回顾性分析罗沙司他使用前后低危骨髓增生异常综合征患者贫血、铁代谢、血脂及炎症指标等变化，以评价其治疗效果及安全性，为罗沙司他在低危骨髓增生异常综合征中的应用提供理论及实践数据。.